Table 2.
Comparison of surgical resection versus transarterial chemoembolization with or without radiofrequency ablation of patients withBCLC stage B hepatocellular carcinoma after propensity score matching
| Variable | SR (n = 140) | TACE+RFA (n = 16) | P-value | SR (n = 140) | TACE (n = 87) | P-value |
|---|---|---|---|---|---|---|
| Male | 117 (83.6) | 13 (81.3) | 0.220 | 117 (83.6) | 67 (77.0) | 0.813 |
| Age (years) | 62 (35–82) | 66 (35–87) | 0.249 | 62 (35–82) | 64 (36–87) | 0.121 |
| Smoking | 68 (48.6) | 8 (50.0) | 0.472 | 68 (48.6) | 38 (43.7) | 0.914 |
| Alcohol use | 58 (41.4) | 7 (43.8) | 0.858 | 58 (41.4) | 35 (40.2) | 0.858 |
| HBV positive | 70 (50.0) | 10 (62.5) | 0.206 | 70 (50.0) | 36 (41.4) | 0.343 |
| HCV positive | 30 (21.4) | 6 (16.7) | 0.069 | 30 (21.4) | 26 (29.8) | 0.148 |
| Total Bilirubin | 1.03 ± 0.43 | 1.21 ± 0.54 | 0.186 | 1.03 ± 0.43 | 1.11 ± 0.50 | 0.061 |
| INR | 1.00 ± 0.06 | 1.04 ± 0.10 | 0.061 | 1.00 ± 0.06 | 1.03 ± 0.09 | 0.051 |
| Cirrhosis | 36 (25.7) | 6 (37.5) | 0.098 | 36 (25.7) | 31 (35.6) | 0.111 |
| Child-Pugh class A | 134 (95.7) | 14 (87.5) | 0.236 | 134 (95.7) | 80 (92.7) | 0.158 |
| Tumor size | 8.2 ± 3.3 | 6.6 ± 2.8 | 0.903 | 8.2 ± 3.3 | 8.2 ± 3.5 | 0.063 |
| Tumor size≥5 cm | 127 (90.7) | 12 (75.0) | 0.186 | 127 (90.7) | 75 (86.2) | 0.071 |
| Tumor number (≥3) | 49 (35.0) | 9 (56.2) | 0.075 | 49 (35.0) | 41 (47.1) | 0.058 |
| AFP (ng/mL) ≥ 200 | 34 (24.3) | 2 (12.5) | 0.405 | 34 (24.3) | 17 (19.5) | 0.289 |
| Mortality | 50 (35.7) | 11 (68.8) | < 0.0001 | 50 (35.7) | 70 (80.5) | 0.010 |
| Follow up times (months) | 39 (1–98) | 26 (9–76) | < 0.0001 | 39 (1–98) | 21 (2–97) | 0.240 |
BCLC stage Barcelona clinic liver cancer; SR Surgical resection; TACE Transcatheter arterial chemoembolization; RFA Radiofrequency ablation; HBV Hepatitis B virus; HCV Hepatitis C virus; AFP: INR International normalize ratio; Alpha-fetoprotein;